Multi-modal proteomics to understand and overcome adaptive drug-resistance mechanisms in FLT3-mutated AML (B03)

• Subject Area: Hematology, Oncology
• Term: since 2025
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 533056198

Project B03 will apply multi-modal proteomics to understand and overcome adaptive drug-resistance mechanisms in FLT3-mutated AML. Using primary AML cells, PDX and cell line models, and CRISPR-based screens, drug screens, RNAseq and proteomic approaches B03 will decipher how plasticity of FLT3-mutated AML cells leads to TKI-resistance, and will identify novel vulnerabilities in TKI-resistant cells.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1709: Cellular Plasticity in Myeloid Malignancies: From Mechanisms to Therapies
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Heads: Dr. Maximilian Blank; Professor Dr. Jeroen Krijgsveld